FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Hahn Mark W						2. Issuer Name and Ticker or Trading Symbol Verona Pharma plc [VRNA]									k all app Direc	tor		rson(s) to Is 10% Ov Other (s	vner	
(Last) 3 MORE	(Fir	,		3. Date of Earliest Transaction (Month/Day/Year) 08/07/2024										Officer (give title below) Chief Financi		ncial	below)	вреспу		
RIVERSIDE					4. If a	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person						
(Street)	N X0	S	E1 2F	RE										V		filed by Mo		•		
(City)	(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication														
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																		
		Table	I - No	on-Deriva	tive	Secui	rities A	cqı	uired	l, Dis	sposed of	or B	enefic	cially	/ Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/						Execution Date			3. Transa Code (I 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3,			4 and 5) Se Be Ov		. Amount of Securities Seneficially Owned Following Reported		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Pric	e	Transa	action(s) 3 and 4)			(311.4)	
Ordinary Shares ⁽¹⁾ 08/07/20)24			A ⁽²⁾		800,000	A	\$	<mark>0</mark>	15,654,488			D		
Ordinary Shares ⁽¹⁾ 08/07/20					024				F		314,800(3)	D	\$2.	62(4)	15,339,688(5)			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Executity or Exercise (Month/Day/Year) if an			eemed Ition Date, h/Day/Year)	4. Transa Code 8)	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration I (Month/Day		ate	7. Title Amour Securi Underl Deriva Securi 3 and 4	nt of ties ying tive ty (Instr	De Se (In:	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D) or Indirect (I) (Instr.	Ownership	Beneficial Ownership (Instr. 4)	
			Code	v	(A) (E		Date Exerci	isable	Expiration Date		Amoun or Numbe of Shares									

Explanation of Responses:

- 1. Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- 2. Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine.
- 3. Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of the Performance Restricted Share Units described in footnote 2 above.
- 4. The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on August 6, 2024 divided by eight (8).
- 5. Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 12,514,688 Ordinary Shares underlying 1,564,336 ADSs.

/s/ Andrew Fisher, Attorneyin-Fact for Mark Hahn

08/09/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.